Targeted Immunotherapy with Rituximab Leads to a Transient Alteration of the IgG Autoantibody Profile in Pemphigus Vulgaris
In pemphigus vulgaris (PV), IgG autoantibodies against the ectodomain of desmoglein 3 (Dsg3) have been shown to be directly responsible for the loss of keratinocyteadhesion. The aim of the present study was to study the effect of the B cell depleting anti-CD20 monoclonal antibody, rituximab, on the...
Saved in:
| Main Authors: | Ralf Müller, Nicolas Hunzelmann, Vera Baur, Guido Siebenhaar, Elke Wenzel, Rüdiger Eming, Andrea Niedermeier, Philippe Musette, Pascal Joly, Michael Hertl |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | Dermatology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2010/321950 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The first case of paraneoplastic pemphigus positive for IgG autoantibodies against integrin α6
by: Ying Li, et al.
Published: (2025-04-01) -
Rituximab in the Management of a Child with Pemphigus Vulgaris: Case Study
by: Nikolay N. Murashkin, et al.
Published: (2022-11-01) -
Role of Desmoglein Autoantibody in the Diagnosis of Pemphigus Vulgaris: A Case Report
by: Diane Lukito Setiawan, et al.
Published: (2025-07-01) -
Ultra-Low-Dose Rituximab in Pemphigus Vulgaris: How Low is the Lowest?
by: Nayankumar H. Patel, et al.
Published: (2025-07-01) -
The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study
by: Xingli Zhou, et al.
Published: (2024-12-01)